Rachel Farrell

Summary

Affiliation: University College London
Country: UK

Publications

  1. ncbi request reprint Emerging therapies in multiple sclerosis
    Rachel Farrell
    Department of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, UK
    Expert Opin Emerg Drugs 10:797-816. 2005
  2. doi request reprint Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice
    R A Farrell
    University College London, Institute of Neurology, London, UK
    Mult Scler 17:1333-40. 2011
  3. ncbi request reprint Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta
    R Farrell
    National Hospital for Neurology and Neurosurgery, Institute of Neurology, Queen Square, London, UK
    Mult Scler 14:212-8. 2008
  4. pmc Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI
    R A Farrell
    Department of Neuroinflammation, Institute of Neurology, UCL, Queen Square, London, UK
    Neurology 73:32-8. 2009
  5. doi request reprint Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients
    Regina Lam
    Neuro Immunology Laboratory, University of British Columbia, Vancouver, Canada
    J Immunol Methods 336:113-8. 2008
  6. ncbi request reprint Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis
    Rachel Farrell
    J Int Med Res 36:204-8; author reply 208-10. 2008

Detail Information

Publications6

  1. ncbi request reprint Emerging therapies in multiple sclerosis
    Rachel Farrell
    Department of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, UK
    Expert Opin Emerg Drugs 10:797-816. 2005
    ..Many of the treatments discussed in this review are still at early stages of development, but provide exciting potential treatment options; others have proved disappointing in larger extended-phase studies...
  2. doi request reprint Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice
    R A Farrell
    University College London, Institute of Neurology, London, UK
    Mult Scler 17:1333-40. 2011
    ..With increasing treatment choice for patients, routine NAb testing should be incorporated to aid therapeutic decisions...
  3. ncbi request reprint Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta
    R Farrell
    National Hospital for Neurology and Neurosurgery, Institute of Neurology, Queen Square, London, UK
    Mult Scler 14:212-8. 2008
    ..Interferon-beta (IFNbeta) is a biological therapy which is immunogenic, inducing anti-IFN-beta neutralizing antibodies (Nabs) in some subjects. The frequency of Nabs varies depending on IFN-beta product and the Nab assay used...
  4. pmc Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI
    R A Farrell
    Department of Neuroinflammation, Institute of Neurology, UCL, Queen Square, London, UK
    Neurology 73:32-8. 2009
    ..Evidence suggests that Epstein-Barr virus (EBV) plays a role in triggering or perpetuating disease activity in multiple sclerosis (MS)...
  5. doi request reprint Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients
    Regina Lam
    Neuro Immunology Laboratory, University of British Columbia, Vancouver, Canada
    J Immunol Methods 336:113-8. 2008
    ..8-29.3%, and the intra-assay coefficient of variation was between 6.3-15.2%. The luciferase assay is reliable, appropriately sensitive and requires less time than the currently available NAb methods...
  6. ncbi request reprint Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis
    Rachel Farrell
    J Int Med Res 36:204-8; author reply 208-10. 2008